UBS lowered the firm’s price target on Waters to $285 from $302 and keeps a Neutral rating on the shares. The company’s Q3 results saw “strong Pharma ex-China” business, though its Q4 guide was a miss and the management cut Fy23 outlook given the tough environment, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WAT: